EJP RD launched its second Joint Transnational Call (JTC2020) co-funded with the European Commission to fund multilateral “Pre-Clinical Research to Develop Effective Therapies for Rare Diseases”. The Project - TREATKCNQ : Targeted treatment for KCNQ related encephalopathies: retigabine analogues, repurposed drugs and allele specific knock down received the approval and founded.
EJP RD launched its second Joint Transnational Call (JTC2020) co-funded with the European Commission to fund multilateral “Pre-Clinical Research to Develop Effective Therapies for Rare Diseases”. The Project -SCN1A-up! : Therapeutic strategies for Dravet syndrome: upregulation of endogenous SCN1A and modulation of remodeling received the approval and founded.
Riconosciuta come personalità giuridica con provvedimento della Giunta Regionale del Veneto del 09.12.2015 n° 815.
Convenzionata con l’AOUI di Verona Prot. 1306 del 12/01/2021. Approvata con Delibera nr. 1392 del 30/12/2020
Link Veloci
Contattaci
© 2021 Dravet Italia Onlus All Rights Reserved. C.F. 90018630237 - Privacy Policy - Cookie Policy